A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science

@article{Borup2016APS,
  title={A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science},
  author={Gitte Borup and Karin Friis Bach and Merete Schmiegelow and Helle Wallach-Kildemoes and Ole Jannik Bjerrum and Niels Westergaard},
  journal={Therapeutic Innovation \& Regulatory Science},
  year={2016},
  volume={50},
  pages={304 - 311}
}
The Copenhagen Centre for Regulatory Science (CORS) and Biopeople at the University of Copenhagen held a workshop in May 2015 titled “Patient Involvement in Medicines Development and Approvals: A Paradigm Shift Towards True Patient Impact in Medicines Development and Regulatory Science” that acknowledged the importance of having patients more involved in the entire process of medicines research and development (R&D) and life cycle management. Four key stakeholders, representing patients… 

Figures and Tables from this paper

EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Regulatory Processes
TLDR
The guidance in this article covers patient involvement in the regulatory field and draws on the mature “Framework for interaction between the European Medicines Agency and patients and consumers and their organizations”, specifically including National Competent Authorities (NCAs).
How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.
TLDR
The pharmaceutical industry appears to be the largest influencer with regard to patients' role in drug development, and the pharmaceutical industry, patient organizations, and regulatory authorities were labeled as "pioneer/dominant," "unaware/quiet," and "hesitant," respectively.
The Role of European Patient Organizations in Pharmacovigilance
TLDR
Patient organizations appear to have an important role in encouraging patients to talk with their doctors/pharmacists about ADRs experienced, or to help him/her report the ADRs to the pharmacovigilance systems.
Patient Engagement at a Tipping Point—The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders
TLDR
Insightful insights gleaned from the DIA conference, “Patient Engagement in Benefit-Risk Assessment throughout the Life Cycle of Medical Products” (September 2015), highlight the changes that will need to occur within the patient, medical-product sponsor, and regulatory cultures in order for patient engagement to become integrated into the medical- product development process and life cycle maintenance.
Evaluating the “return on patient engagement initiatives” in medicines research and development: A literature review
  • L. Vat, T. Finlay, J. Broerse
  • Medicine, Political Science
    Health expectations : an international journal of public participation in health care and health policy
  • 2019
TLDR
This paper is focused on ways to evaluate patient engagement at three decision‐making points in the medicines research and development process: research priority setting, clinical trial design and early dialogues with regulators and health technology assessment bodies.
Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
TLDR
The favourable experiences in this study support further consideration and exploration of this approach to communicate adverse drug reactions to patients, and patient organizations can help enable effective communication of adverseDrug reactions to a relevant audience.
Diabetes patient’s pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation
TLDR
Patients with diabetes showed greater understanding of ADRs and higher need to report them than patients without diabetes, and patient organisations are well positioned to be a source where patients can obtain reliable information, changing their attitudes and perceptions about the disease and drug treatments.
The Rules of Engagement
TLDR
Pat groups are developing diverse skillsets and acquiring assets to leverage in order to become collaborators with industry and academia on clinical trials, but there are still mindsets to change, and stakeholders need further guidance on operationalizing a new model of clinical trial conduct.
Patient and Public Involvement in Dermatology Research: A Review
TLDR
The principles of PPI are explained and the existing evidence base at each research stage is examined to explore whether the specialty has effectively harnessed this approach and to identify any subsequent impact of PSI.
...
1
2
...

References

SHOWING 1-10 OF 23 REFERENCES
EUPATI: Collaboration between patients, academia and industry to champion the informed patient in the research and development of medicines
TLDR
The successful uptake of EUPATI’s materials will hopefully translate into a new paradigm of increased patient involvement across the entire medicines research and development process, bringing mutual benefit to all stakeholders, including better medicines.
Partnering With Patients in the Development and Lifecycle of Medicines
TLDR
It is essential that all stakeholders participate to drive adoption and implementation of the framework and to ensure that patients and their needs are embedded at the heart of medicines development and lifecycle management.
Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
  • C. Acquadro, R. Berzon, M. Rothman
  • Medicine
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2003
TLDR
The February 16, 2001, meeting represented an important step in harmonizing efforts across various organizations and in opening a dialogue with the FDA around major issues related to methodologic standards for measuring and interpreting PROs in the drug evaluation process.
Patient Engagement by Pharma—Why and How? A Framework for Compliant Patient Engagement
  • L. Dewulf
  • Medicine, Political Science
    Therapeutic innovation & regulatory science
  • 2015
TLDR
A patient engagement framework has been developed at UCB and shared publicly as a contribution to setting and raising standards in patient engagement, with the ultimate aim of fostering the development of better solutions for people living with medical issues.
Pharmacovigilance: methods, recent developments and future perspectives
TLDR
To review and discuss various aspects of pharmacovigilance, including new methodolgical developments, which include transparency and increased patient involvement are two important elements.
‘Is it worth doing?’ Measuring the impact of patient and public involvement in research
  • K. Staley
  • Business
    Research Involvement and Engagement
  • 2015
TLDR
This review reflects on the use of quantitative approaches to evaluating impact and concludes that the statistical evidence is weakened by not paying sufficient attention to the context in which involvement takes place and the way it is carried out.
Patients’, clinicians’ and the research communities’ priorities for treatment research: there is an important mismatch
TLDR
The findings confirm the mismatch first described by Tallon et al. 15 years ago and suggest that the research community should make greater efforts to address issues of importance to users of research, such as patients and healthcare professionals.
Consumers' reports of suspected adverse drug reactions volunteered to a consumer magazine.
TLDR
This study investigated the information about possible ADRs provided by consumers who had easy reporting access via the internet via an open access website and confirmed that patients report rather unspecific symptoms, e.g. indisposition, dizziness and insomnia.
The role of users in innovation in the pharmaceutical industry.
...
1
2
3
...